ISPOR 17th Annual International Meeting
June 2-6, 2012, Washington, DC, USA
Search:
 
Value-based Decision Making in Rheumatic Disease : What does it mean for pharmacists ?
Médicaments Issus des Biotechnologies : Différencier Les Prix selon la Valeur
Comments on : Performance-Based Risk-Sharing Arrangements - Good practice for design, implementation and evaluation. An ISPOR Task force review
EUnetHTA : Draft Guidelines - Endpoints used for REA of pharmaceuticals HEALTH-RELATED QUALITY OF LIFE and UTILITY MEASURES
Home Publications Publications 2005-2009

Le Lay K., Francesconi C., Briand Y., Souchet T., Launois R.

Population-based budget impact model of aprepitant (Emend) in Highly Emetogenic cisplatine-based Chemotherapy (HEC)

ISPOR 8th Annual European Congress, 6-8 November 2005, Florence, PCN3.



(PDF, 240.7 ko)